Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 5/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.32 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301982 | 0.88 | TYK2 (0.37) | ATRTYK2SYKBRSK1IRAK4 | |
| SCHEMBL301984 | 0.88 | TYK2 (0.37) | ATRTYK2SYKBRSK1IRAK4 | |
| SCHEMBL302379 | 0.84 | CA12 (0.35) | ATRATRIPBRAFALDH1A1LMNA | |
| SCHEMBL302115 | 0.84 | MCHR1 (0.34) | ATRATRIPSYKBRAFALDH1A1 | |
| SCHEMBL302287 | 0.84 | ALDH1A1 (0.40) | ATRATRIPALDH1A1LMNANPSR1 | |
| SCHEMBL302309 | 0.80 | ATR (0.42) | ATRATRIPTYK2SYKBRSK1 | |
| SCHEMBL303501 | 0.79 | ATR (0.41) | ATRATRIPTYK2SYKBRSK1 | |
| SCHEMBL302590 | 0.79 | KDM4E (0.41) | ATRATRIPTYK2SYKBRSK1 | |
| SCHEMBL303427 | 0.79 | ATR (0.39) | ATRATRIPTYK2SYKBRSK1 | |
| SCHEMBL301886 | 0.78 | ATR (0.38) | ATRATRIPTYK2SYKBRSK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4851337-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| EP-1689403-A4 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2007-09-05 | — | — | EP | claimed |
| JP-2007510748-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1689403-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | claimed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | claimed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1689403-A4 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1689403-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | ATR 4882/4885ATRIP 4870/4885TYK2 826/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | ATR 4840/4885ATRIP 4812/4885TYK2 2464/4885 |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | MMP12, IL1RN, CASP12 | ATR 4363/4885ATRIP 3915/4885TYK2 3469/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | ATR 4830/4885ATRIP 4176/4885TYK2 1275/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | ATR 4840/4885ATRIP 4812/4885TYK2 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.